News Sentiment

PFE sentiment intelligence

Pfizer Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 46 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 24.17 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

-0.6% over one week, -7.8% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Is Earlier‑Stage PADCEV‑Keytruda Approval Reshaping The Investment Case For Pfizer (PFE)?

Market Reaction

Balanced read

49/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -0.6% Price digesting
Trend fit Trend inactive -7.8% over four weeks
Fair value -2.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 30
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
TradingView 5
24/7 Wall St. 3
The Globe and Mail 3
Simply Wall Street 2
Reuters 2
Sahm 2
TechStock² 1

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 8
Regulatory and legal 7
Deals and strategy 5
Capital return 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 46
Simply Wall Street Direct company coverage

Is Earlier‑Stage PADCEV‑Keytruda Approval Reshaping The Investment Case For Pfizer (PFE)?

Pfizer and Astellas recently secured FDA approval for PADCEV plus Keytruda for earlier-stage muscle-invasive bladder cancer, which broadens PADCEV’s application and reinforces Pfizer's oncology focus. While this strengthens Pfizer’s near-term cancer pipeline, the article notes th

Tone
Positive 62/100
Event
Regulatory and legal
Published
16 Jul 2026 00:41
Source
Simply Wall Street
MarketWatch Direct company coverage

Pfizer Inc. stock outperforms competitors on strong trading day

Pfizer Inc. (PFE) saw its stock rise by 2.35% to $24.82 on Wednesday, outperforming the broader market as both the S&P 500 and Dow Jones Industrial Average also posted gains. The company's stock closed 13.65% below its 52-week high of $28.75, which was set on April 2nd. This perf

Tone
Positive 72/100
Event
Market update
Published
15 Jul 2026 16:36
Source
MarketWatch
Reuters Direct company coverage

Sanofi sues Pfizer, Moderna over COVID shot technology

Sanofi has filed lawsuits against Pfizer and Moderna, alleging that their COVID-19 vaccines infringe on multiple patents held by the French pharmaceutical company. The lawsuits claim that the mRNA innovations used in Pfizer and Moderna's blockbuster vaccines violate Sanofi's pate

Tone
Negative 33/100
Event
Regulatory and legal
Published
15 Jul 2026 16:04
Source
Reuters
Bloomberg Law News Direct company coverage

Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties

Sanofi has filed federal lawsuits against Moderna and Pfizer, seeking patent royalties for their COVID-19 and RSV vaccines. Sanofi alleges that Moderna's Spikevax, mNexspike, and mResvia vaccines, and Pfizer's Comirnaty vaccine, infringe upon as many as 10 mRNA delivery patents h

Tone
Negative 38/100
Event
Regulatory and legal
Published
15 Jul 2026 14:59
Source
Bloomberg Law News
Market source Direct company coverage

Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC

Pfizer and Astellas Pharma announced FDA approval of PADCEV plus Keytruda as a neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), marking the first platinum-free regimen approved for MIBC regardless of cisplatin eligibility. This app

Tone
Neutral 50/100
Event
Regulatory and legal
Published
15 Jul 2026 14:24
Source
Market source
24/7 Wall St. Direct company coverage

Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?

Pfizer and Gilead Sciences are presenting a contrarian investment opportunity as both stocks have experienced "death crosses" but trade below Wall Street consensus targets. Pfizer appears to be the more compelling contrarian setup due to its attractive 8x forward P/E and 7% divid

Tone
Positive 60/100
Event
Market update
Published
15 Jul 2026 13:10
Source
24/7 Wall St.
Market source Direct company coverage

Celcuity gains FDA approval for closely-watched breast cancer drug

Celcuity received FDA approval for its breast cancer drug Revtorpyk, to be used in combination with hormone therapy and Pfizer’s Ibrance for certain advanced ER-positive, HER2-negative patients. Despite this regulatory win, Celcuity's shares fell due to unexpected launch timing a

Tone
Positive 66/100
Event
Regulatory and legal
Published
15 Jul 2026 07:18
Source
Market source
Propmodo Direct company coverage

Structural Failure at Pfizer Conversion Project Triggers Citywide Construction Review

A structural failure at the former Pfizer headquarters conversion project into 1,600 apartments in New York City has led to a citywide safety inspection of construction sites. Two steel columns buckled, causing floors to sag and prompting evacuations, raising concerns among inves

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 22:09
Source
Propmodo
Market source Direct company coverage

CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug

Celcuity Inc. (CELC) shares surged 7% after the FDA approved its cancer drug, gedatolisib, in combination with fulvestrant, with or without Pfizer's palbociclib, for advanced hormone receptor-positive, HER2-negative breast cancer. This marks Celcuity's first marketed product, tra

Tone
Positive 72/100
Event
Regulatory and legal
Published
14 Jul 2026 21:24
Source
Market source
Simply Wall Street Direct company coverage

Pfizer (PFE) Stock Looks Fully Priced After Its 21% Slump

Pfizer (PFE) shares have declined by 21% over the past five years, placing its current valuation in a neutral position—neither clearly cheap nor expensive. The stock trades at a P/E ratio of 18.7x, close to Simply Wall St's fair P/E of 19.6x, suggesting it is fairly valued within

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 17:40
Source
Simply Wall Street
24/7 Wall St. Direct company coverage

Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen

This article contrasts Pfizer and Amgen, arguing that Pfizer offers a better investment in oncology due to its successful integration of Seagen and existing revenue streams. Pfizer trades at a lower forward P/E of 8x with a substantial 7% dividend yield, while Amgen faces signifi

Tone
Positive 67/100
Event
Earnings
Published
14 Jul 2026 15:51
Source
24/7 Wall St.
The Globe and Mail Direct company coverage

Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?

Pfizer currently boasts the highest dividend yield in the S&P 500 at 7.1%, which is significantly above the average, leading some investors to worry about the safety of its dividend. While the high yield is partly due to a volatile share price, the company's recent earnings show

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 15:04
Source
The Globe and Mail
TradingView Direct company coverage

Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results

Pfizer is a leading oncology drugmaker, with oncology sales comprising about 27% of its total revenues. The company will announce its Q2 2026 results on August 4, with expectations of growth driven by drugs like Padcev, Lorbrena, and the Braftovi-Mektovi combination, alongside co

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 14:08
Source
TradingView